Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 20/20 | 0.74 |
| ▸ | FNTB | P49356 | 20/20 | 0.74 |
| ▸ | HRAS | P01112 | 1/20 | 0.74 |
| ▸ | KRAS | P01116 | 1/20 | 0.74 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-214662 SCHEMBL134853 | 1.00 | FNTA (0.74) | FNTAFNTBHRASKRASPGGT1B | |
| Bms-214662 SCHEMBL29454371 | 1.00 | FNTA (0.74) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL6617456 | 0.93 | FNTA (0.64) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3501155 | 0.92 | FNTA (0.63) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3499280 | 0.90 | FNTA (0.73) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3499278 | 0.90 | FNTA (0.73) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL13186538 | 0.89 | FNTA (0.58) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3502128 | 0.89 | FNTA (0.71) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3500829 | 0.89 | FNTA (0.71) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL3501186 | 0.88 | FNTA (0.59) | FNTAFNTBHRASKRASPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931677-B1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-20 | — | — | EP | claimed |
| US-20120238019-A1 | STEM CELL CULTURE MEDIA FOR MAINTAINING STEMNESS OR INDUCING DIFFERENTIATION OF STEM CELLS | COLLEGE OF MEDICINE POCHON CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2012-09-20 | — | — | US | claimed |
| EP-1272193-B1 | SYNERGISTIC COMBINATION THERAPY FOR TREATING CANCER | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | claimed |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | claimed |
| US-7157446-B2 | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | claimed |
| US-7074921-B2 | Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-07-11 | — | — | US | claimed |
| EP-1656931-A1 | Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease | Exonhit Therapeutics SA (FR) | 2006-05-17 | — | — | EP | claimed |
| EP-1622628-A2 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR, A CYCLODEXTRIN, AND ETHANOL | Bristol-Myers Squibb Company (US) | 2006-02-08 | — | — | EP | claimed |
| EP-1443936-A4 | PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUTED-2,3,4,5- TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | claimed |
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-12-08 | — | — | US | claimed |
| US-6537988-B2 | Imidazole-1h-1,4-benzodiazepine derivatives along with antiproliferative cytotoxic and cytostatic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-25 | — | — | US | claimed |
| EP-1272193-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Bristol-Myers Squibb Company (US) | 2003-01-08 | — | — | EP | claimed |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-14 | — | — | US | claimed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | claimed |
| EP-1143796-A4 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-BETA-CYCLODEXTRIN OR 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2002-03-20 | — | — | EP | claimed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | claimed |
| EP-1143796-A1 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-BETA-CYCLODEXTRIN OR 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001072721-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-04 | — | — | WO | claimed |
| US-6218375-B1 | AS ANTI-TUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2001-04-17 | — | — | US | claimed |
| WO-2000042849-A1 | COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-07-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272722-A1 | Methods for the treatment of synucleinopathies | SNCA, PARK7, NLN | FNTA 24/4885FNTB 49/4885HRAS 588/4885 |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | FNTB, ACAT2, SOAT2 | FNTA 7/4885FNTB 1/4885HRAS 2139/4885 |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | FNTA, GGPS1, FNTB | FNTA 1/4885FNTB 3/4885HRAS 403/4885 |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | ABCB11, TP53, SLC10A1 | FNTA 1166/4885FNTB 1798/4885HRAS 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.